Polypharmacy Frequency: The Relationship Between
Polypharmacy and Mortality in COVID-19 (+) Older Adults

Ertürk Zararsız, Gözde; Akın, Sibel; TÜRE, Zeynep Ture; DURMUS, Nurdan SENTURK; Soysal, Tuba

doi:10.4274/ejgg.galenos.2021.478

Polypharmacy Frequency: The Relationship Between Polypharmacy and Mortality in COVID-19 (+) Older Adults

Nurdan SENTURK DURMUS, (Erciyes Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Geriatri Anabilim Dalı, Kayseri, Türkiye)

Sibel AKIN, (Erciyes Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Geriatri Anabilim Dalı, Kayseri, Türkiye)

Tuba SOYSAL, (Erciyes Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Geriatri Anabilim Dalı, Kayseri, Türkiye)

Gözde ERTÜRK ZARARSIZ, (Erciyes Üniversitesi, Tıp Fakültesi, Biyoistatistik Anabilim Dalı, Kayseri, Türkiye)

Zeynep TÜRE (Erciyes Üniversitesi, Tıp Fakültesi Klinik Mikrobiyoloji ve Enfeksiyon Anabilim Dalı, Kayseri, Türkiye)

European journal of geriatrics and gerontology (Online)

0 0

Yıl: 2022 Cilt: 4 Sayı: 1 Sayfa Aralığı: 5 - 10 Metin Dili: İngilizce DOI: 10.4274/ejgg.galenos.2021.478 İndeks Tarihi: 29-06-2022

Polypharmacy Frequency: The Relationship Between Polypharmacy and Mortality in COVID-19 (+) Older Adults

Öz:

Objective: This study aims to determine the relationship between polypharmacy and Coronavirus disease-2019 (COVID-19) (+) related mortality. Materials and Methods: All older adults >60 years old who had positive COVID-19 polymerase chain reaction tests were included in the study, designed retrospectively. Polypharmacy was defined as drug use of five or more. Results: One hundred and ten people of >60 years old were included in the study. Fifty-nine (53.6%) of the participants were male and the mean age was 70.5+8.81. The prevalence of polypharmacy in patients diagnosed with COVID-19 infection was 31.8% (n=35). Eighty-two (78.8%) of participants had pneumonia. Mortality occurred in 24 (21.8%) of the participants. There was no relationship between polypharmacy and mortality (p=0.241). In multivariate analysis, older age was associated with mortality (odds ratio: 6.82 95% confidence interval: 2.46-18.91, p<0.001). Conclusion: The prevalence of polypharmacy in individuals diagnosed with COVID-19 infection was like the literature. The most significant factors in death in people with COVID-19 infection were older age. There was no relationship between polypharmacy and mortality.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. https://coronavirus.jhu.edu/map.html.
2. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054-1062.
3. Esme M, Koca M, Dikmeer A, Balci C, Ata N, Dogu BB, Cankurtaran M, Yilmaz M, Celik O, Unal GG, Ulgu MM, Birinci S. Older Adults With Coronavirus Disease 2019: A Nationwide Study in Turkey. J Gerontol A Biol Sci Med Sci 2021;76:e68-e75.
4. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507-513.
5. Medetalibeyoglu A, Senkal N, Kose M, Catma Y, Bilge Caparali E, Erelel M, Oral Oncul M, Bahat G, Tukek T. Older Adults Hospitalized with Covid-19: Clinical Characteristics and Early Outcomes from a Single Center in Istanbul, Turkey. J Nutr Health Aging 2020;24:928-937.
6. De Smet R, Mellaerts B, Vandewinckele H, Lybeert P, Frans E, Ombelet S, Lemahieu W, Symons R, Ho E, Frans J, Smismans A, Laurent MR. Frailty and Mortality in Hospitalized Older Adults With COVID-19: Retrospective Observational Study. J Am Med Dir Assoc 2020;21:928-932.e1.
7. Li T, Lu L, Zhang W, Tao Y, Wang L, Bao J, Liu B, Duan J. Clinical characteristics of 312 hospitalized older patients with COVID-19 in Wuhan, China. Arch Gerontol Geriatr 2020;91:104185.
8. Ministry of Health - Republic of Turkey https://covid19.saglik.gov.tr/.
9. Franchi C, Tettamanti M, Pasina L, Djignefa CD, Fortino I, Bortolotti A, Merlino L, Nobili A. Changes in drug prescribing to Italian communitydwelling elderly people: the EPIFARM-Elderly Project 2000-2010. Eur J Clin Pharmacol 2014;70:437-443.
10. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr 2017;17:230.
11. Wastesson JW, Morin L, Tan ECK, Johnell K. An update on the clinical consequences of polypharmacy in older adults: a narrative review. Expert Opin Drug Saf 2018;17:1185-1196.
12. Fulton MM, Allen ER. Polypharmacy in the elderly: a literature review. J Am Acad Nurse Pract 2005;17:123-132.
13. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 2002;287:337-344.
14. Gutiérrez-Valencia M, Izquierdo M, Cesari M, Casas-Herrero Á, Inzitari M, Martínez-Velilla N. The relationship between frailty and polypharmacy in older people: A systematic review. Br J Clin Pharmacol 2018;84:1432-1444.
15. Knopp P, Miles A, Webb TE, Mcloughlin BC, Mannan I, Raja N, Wan B, Davis D. Presenting features of COVID-19 in older people: relationships with frailty, inflammation and mortality. Eur Geriatr Med 2020;11:1089-1094.
16. Singh AK, Khunti K. Assessment of risk, severity, mortality, glycemic control and antidiabetic agents in patients with diabetes and COVID-19: A narrative review. Diabetes Res Clin Pract 2020;165:108266.
17. Luo P, Qiu L, Liu Y, Liu XL, Zheng JL, Xue HY, Liu WH, Liu D, Li J. Metformin Treatment Was Associated with Decreased Mortality in COVID-19 Patients with Diabetes in a Retrospective Analysis. Am J Trop Med Hyg 2020;103:69- 72.
18. Rodilla E, Saura A, Jiménez I, Mendizábal A, Pineda-Cantero A, Lorenzo- Hernández E, Fidalgo-Montero MDP, López-Cuervo JF, Gil-Sánchez R, Rabadán-Pejenaute E, Abella-Vázquez L, Giner-Galvañ V, Solís-Marquínez MN, Boixeda R, Peña-Fernández A, Carrasco-Sánchez FJ, González-Moraleja J, Torres-Peña JD, Guisado-Espartero ME, Escobar-Sevilla J, Guzmán-García M, Martín-Escalante MD, Martínez-González ÁL, Casas-Rojo JM, Gómez- Huelgas R. Association of Hypertension with All-Cause Mortality among Hospitalized Patients with COVID-19. J Clin Med 2020;9:3136.
19. Chen R, Yang J, Gao X, Ding X, Yang Y, Shen Y, He C, Xiang H, Ke J, Yuan F, Cheng R, Lv H, Li P, Zhang L, Liu C, Tan H, Huang L. Influence of blood pressure control and application of renin-angiotensin-aldosterone system inhibitors on the outcomes in COVID-19 patients with hypertension. J Clin Hypertens (Greenwich) 2020;22:1974-1983.
20. De Spiegeleer A, Bronselaer A, Teo JT, Byttebier G, De Tré G, Belmans L, Dobson R, Wynendaele E, Van De Wiele C, Vandaele F, Van Dijck D, Bean D, Fedson D, De Spiegeleer B. The Effects of ARBs, ACEis, and Statins on Clinical Outcomes of COVID-19 Infection Among Nursing Home Residents. J Am Med Dir Assoc 2020;21:909-914.e2.
21. Rodriguez-Nava G, Trelles-Garcia DP, Yanez-Bello MA, Chung CW, Trelles- Garcia VP, Friedman HJ. Atorvastatin associated with decreased hazard for death in COVID-19 patients admitted to an ICU: a retrospective cohort study. Crit Care 2020;24:429.
22. Inama G, Dodi C, Provini M, Bossoni E, Inama L, Balzarini L, Mancini C, Ramponi S, Marvisi M. Coronavirus disease 2019 infection in patients with recent cardiac surgery: does chronic anticoagulant therapy have a protective effect? J Cardiovasc Med (Hagerstown) 2020;21:765-771.
23. Tremblay D, van Gerwen M, Alsen M, Thibaud S, Kessler A, Venugopal S, Makki I, Qin Q, Dharmapuri S, Jun T, Bhalla S, Berwick S, Feld J, Mascarenhas J, Troy K, Cromwell C, Dunn A, Oh WK, Naymagon L. Impact of anticoagulation prior to COVID-19 infection: a propensity score-matched cohort study. Blood 2020;136:144-147.
24. Kocayigit I, Kocayigit H, Yaylaci S, Can Y, Erdem AF, Karabay O. Impact of antihypertensive agents on clinical course and in-hospital mortality: analysis of 169 hypertensive patients hospitalized for COVID-19. Rev Assoc Med Bras (1992) 2020;66(Suppl 2):71-76.
25. Cheng X, Liu YM, Li H, Zhang X, Lei F, Qin JJ, Chen Z, Deng KQ, Lin L, Chen MM, Song X, Xia M, Huang X, Liu W, Cai J, Zhang XJ, Zhou F, Zhang P, Wang Y, Ma X, Xu Q, Yang J, Ye P, Mao W, Huang X, Xia J, Zhang BH, Guo J, Zhu L, Lu Z, Yuan Y, Wei X, She ZG, Ji YX, Li H. Metformin Is Associated with Higher Incidence of Acidosis, but Not Mortality, in Individuals with COVID-19 and Pre-existing Type 2 Diabetes. Cell Metab 2020;32:537-547.e3.
26. Alamdari NM, Afaghi S, Rahimi FS, Tarki FE, Tavana S, Zali A, Fathi M, Besharat S, Bagheri L, Pourmotahari F, Irvani SSN, Dabbagh A, Mousavi SA. Mortality Risk Factors among Hospitalized COVID-19 Patients in a Major Referral Center in Iran. Tohoku J Exp Med 2020;252:73-84.
27. Kim MK, Jeon JH, Kim SW, Moon JS, Cho NH, Han E, You JH, Lee JY, Hyun M, Park JS, Kwon YS, Choi YK, Kwon KT, Lee SY, Jeon EJ, Kim JW, Hong HL, Kwon HH, Jung CY, Lee YY, Ha E, Chung SM, Hur J, Ahn JH, Kim NY, Kim SW, Chang HH, Lee YH, Lee J, Park KG, Kim HA, Lee JH. The Clinical Characteristics and Outcomes of Patients with Moderate-to-Severe Coronavirus Disease 2019 Infection and Diabetes in Daegu, South Korea. Diabetes Metab J 2020;44:602-613.
28. Zhang G, Zhang J, Wang B, Zhu X, Wang Q, Qiu S. Analysis of clinical characteristics and laboratory findings of 95 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a retrospective analysis. Respir Res 2020;21:74.
29. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, Wang T, Zhang X, Chen H, Yu H, Zhang X, Zhang M, Wu S, Song J, Chen T, Han M, Li S, Luo X, Zhao J, Ning Q. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 2020;130:2620-2629.
30. Ministry of Health - Republic of Turkey https://saglik.gov.tr/.
31. Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? Lancet 2020;395:1225-1228.
32. Opal SM, Girard TD, Ely EW. The immunopathogenesis of sepsis in elderly patients. Clin Infect Dis 2005;41(Suppl 7):S504-S512.
33. Grubeck-Loebenstein B, Wick G. The aging of the immune system. Adv Immunol 2002;80:243-284.
34. Opal SM, Esmon CT. Bench-to-bedside review: functional relationships between coagulation and the innate immune response and their respective roles in the pathogenesis of sepsis. Crit Care 2003;7:23-38.
35. Cohen HJ, Harris T, Pieper CF. Coagulation and activation of inflammatory pathways in the development of functional decline and mortality in the elderly. Am J Med 2003;114:180-187.
36. Yamamoto K, Takeshita K, Kojima T, Takamatsu J, Saito H. Aging and plasminogen activator inhibitor-1 (PAI-1) regulation: implication in the pathogenesis of thrombotic disorders in the elderly. Cardiovasc Res 2005;66:276-285.
37. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020;382:1708-1720.

APA	DURMUS N, Akın S, Soysal T, Ertürk Zararsız G, TÜRE Z (2022). Polypharmacy Frequency: The Relationship Between Polypharmacy and Mortality in COVID-19 (+) Older Adults. , 5 - 10. 10.4274/ejgg.galenos.2021.478
Chicago	DURMUS Nurdan SENTURK,Akın Sibel,Soysal Tuba,Ertürk Zararsız Gözde,TÜRE Zeynep Ture Polypharmacy Frequency: The Relationship Between Polypharmacy and Mortality in COVID-19 (+) Older Adults. (2022): 5 - 10. 10.4274/ejgg.galenos.2021.478
MLA	DURMUS Nurdan SENTURK,Akın Sibel,Soysal Tuba,Ertürk Zararsız Gözde,TÜRE Zeynep Ture Polypharmacy Frequency: The Relationship Between Polypharmacy and Mortality in COVID-19 (+) Older Adults. , 2022, ss.5 - 10. 10.4274/ejgg.galenos.2021.478
AMA	DURMUS N,Akın S,Soysal T,Ertürk Zararsız G,TÜRE Z Polypharmacy Frequency: The Relationship Between Polypharmacy and Mortality in COVID-19 (+) Older Adults. . 2022; 5 - 10. 10.4274/ejgg.galenos.2021.478
Vancouver	DURMUS N,Akın S,Soysal T,Ertürk Zararsız G,TÜRE Z Polypharmacy Frequency: The Relationship Between Polypharmacy and Mortality in COVID-19 (+) Older Adults. . 2022; 5 - 10. 10.4274/ejgg.galenos.2021.478
IEEE	DURMUS N,Akın S,Soysal T,Ertürk Zararsız G,TÜRE Z "Polypharmacy Frequency: The Relationship Between Polypharmacy and Mortality in COVID-19 (+) Older Adults." , ss.5 - 10, 2022. 10.4274/ejgg.galenos.2021.478
ISNAD	DURMUS, Nurdan SENTURK vd. "Polypharmacy Frequency: The Relationship Between Polypharmacy and Mortality in COVID-19 (+) Older Adults". (2022), 5-10. https://doi.org/10.4274/ejgg.galenos.2021.478

APA	DURMUS N, Akın S, Soysal T, Ertürk Zararsız G, TÜRE Z (2022). Polypharmacy Frequency: The Relationship Between Polypharmacy and Mortality in COVID-19 (+) Older Adults. European journal of geriatrics and gerontology (Online), 4(1), 5 - 10. 10.4274/ejgg.galenos.2021.478
Chicago	DURMUS Nurdan SENTURK,Akın Sibel,Soysal Tuba,Ertürk Zararsız Gözde,TÜRE Zeynep Ture Polypharmacy Frequency: The Relationship Between Polypharmacy and Mortality in COVID-19 (+) Older Adults. European journal of geriatrics and gerontology (Online) 4, no.1 (2022): 5 - 10. 10.4274/ejgg.galenos.2021.478
MLA	DURMUS Nurdan SENTURK,Akın Sibel,Soysal Tuba,Ertürk Zararsız Gözde,TÜRE Zeynep Ture Polypharmacy Frequency: The Relationship Between Polypharmacy and Mortality in COVID-19 (+) Older Adults. European journal of geriatrics and gerontology (Online), vol.4, no.1, 2022, ss.5 - 10. 10.4274/ejgg.galenos.2021.478
AMA	DURMUS N,Akın S,Soysal T,Ertürk Zararsız G,TÜRE Z Polypharmacy Frequency: The Relationship Between Polypharmacy and Mortality in COVID-19 (+) Older Adults. European journal of geriatrics and gerontology (Online). 2022; 4(1): 5 - 10. 10.4274/ejgg.galenos.2021.478
Vancouver	DURMUS N,Akın S,Soysal T,Ertürk Zararsız G,TÜRE Z Polypharmacy Frequency: The Relationship Between Polypharmacy and Mortality in COVID-19 (+) Older Adults. European journal of geriatrics and gerontology (Online). 2022; 4(1): 5 - 10. 10.4274/ejgg.galenos.2021.478
IEEE	DURMUS N,Akın S,Soysal T,Ertürk Zararsız G,TÜRE Z "Polypharmacy Frequency: The Relationship Between Polypharmacy and Mortality in COVID-19 (+) Older Adults." European journal of geriatrics and gerontology (Online), 4, ss.5 - 10, 2022. 10.4274/ejgg.galenos.2021.478
ISNAD	DURMUS, Nurdan SENTURK vd. "Polypharmacy Frequency: The Relationship Between Polypharmacy and Mortality in COVID-19 (+) Older Adults". European journal of geriatrics and gerontology (Online) 4/1 (2022), 5-10. https://doi.org/10.4274/ejgg.galenos.2021.478